Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Aerts

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 25, 2018
Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancerLucas Moreno, Michela Casanova, Julia C Chisholm, et al.
Cancers|May 25, 2024
MR Imaging of Adverse Effects and Ocular Growth Decline after Selective Intra-Arterial Chemotherapy for RetinoblastomaChristiaan M de Bloeme, Sabien van Elst, Paolo Galluzzi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2024
Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?Patricia Raiser, Gudrun Schleiermacher, Marion Gambart, et al.
Cancer|February 11, 2025
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastomaSteven G DuBois, Chitose Ogawa, Lucas Moreno, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2024
Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survivalAurore Pire, Theo Z Hirsch, Guillaume Morcrette, et al.
Cancer Discovery|April 24, 2021
Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver CancerTheo Z Hirsch, Jill Pilet, Guillaume Morcrette, et al.
Neuro-Oncology Advances|July 16, 2020
Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade gliomaStephanie Vairy, Gwénaël Le Teuff, Francisco Bautista, et al.
Pediatric Blood & Cancer|September 4, 2025
Atypical Neuroblastoma With Absent Urinary Catecholamine Excretion and <sup>123</sup>ImIBG Avidity Are of Favorable Outcome: A Retrospective French Single-Center StudyAnna Borovkov, Juliette Assy, Isabelle Aerts, et al.
Journal of Hepatology|December 1, 2025
Targeting ATR to overcome cisplatin resistance in hepatoblastomaPierre Morel-Ribeiro, Marianna Cornet, Jill Pilet, et al.
The Journal of Pathology|March 7, 2022
Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patientsMaria Cuadrado-Vilanova, Jing Liu, Sonia Paco, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|June 25, 2018
Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancerLucas Moreno, Michela Casanova, Julia C Chisholm, et al.
Cancers|May 25, 2024
MR Imaging of Adverse Effects and Ocular Growth Decline after Selective Intra-Arterial Chemotherapy for RetinoblastomaChristiaan M de Bloeme, Sabien van Elst, Paolo Galluzzi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2024
Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?Patricia Raiser, Gudrun Schleiermacher, Marion Gambart, et al.
Cancer|February 11, 2025
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastomaSteven G DuBois, Chitose Ogawa, Lucas Moreno, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2024
Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survivalAurore Pire, Theo Z Hirsch, Guillaume Morcrette, et al.
Cancer Discovery|April 24, 2021
Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver CancerTheo Z Hirsch, Jill Pilet, Guillaume Morcrette, et al.
Neuro-Oncology Advances|July 16, 2020
Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade gliomaStephanie Vairy, Gwénaël Le Teuff, Francisco Bautista, et al.
Pediatric Blood & Cancer|September 4, 2025
Atypical Neuroblastoma With Absent Urinary Catecholamine Excretion and <sup>123</sup>ImIBG Avidity Are of Favorable Outcome: A Retrospective French Single-Center StudyAnna Borovkov, Juliette Assy, Isabelle Aerts, et al.
Journal of Hepatology|December 1, 2025
Targeting ATR to overcome cisplatin resistance in hepatoblastomaPierre Morel-Ribeiro, Marianna Cornet, Jill Pilet, et al.
The Journal of Pathology|March 7, 2022
Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patientsMaria Cuadrado-Vilanova, Jing Liu, Sonia Paco, et al.
Pageof 13